It's among the first approved cholesterol-lowering therapies specifically for this genetic risk factor said to affect 20% of ...

L’essai de phase 3 Zenith, chez des adultes à haut risque atteints d’hypertension artérielle pulmonaire (HTAP) et recevant la ...

A groundbreaking experimental medication called lepodisiran is showing extraordinary promise in clinical trials, potentially opening a new chapter in heart disease prevention. Lipoprotein(a ...

Though not yet available, lepodisiran could become a breakthrough treatment for a major cause of heart disease and stroke. An experimental drug seems to nearly eliminate a major—but often ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can increase the risk of heart attacks and strokes.

researchers say Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran "The implementation of this technology is expected to enhance the management of chronic kidney ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can “silence” the main gene responsible for ...

Eli Lilly is working on Lepodisiran, while Amgen is also doing trials for Olpasiran. The world's top pharmaceutical companies are developing drugs to lower a type of cholesterol common among ...

A new experimental drug, lepodisiran, is expected to protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the blood. Made by pharmaceutical giant Eli ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...